Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2019

Open Access 01-04-2019 | Research Article

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

Authors: R. Vera, M. J. Otero, F. Ayala de la Peña, C. González-Pérez, Á. Peñuelas, J. M. Sepúlveda, N. Quer, N. Doménech-Climent, J. A. Virizuela, P. Beorlegui, M. Q. Gorgas

Published in: Clinical and Translational Oncology | Issue 4/2019

Login to get access

Abstract

Aim

To define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment.

Methods

By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list.

Results

In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity.

Conclusions

It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.
Literature
1.
Schwappach DL, Wernli M. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). 2010;19:285–92.CrossRef
2.
Marliot G, Le Rhun E, Sakji I, Bonneterre J, Cazin JL. Securing the circuit of intrathecally administered cancer drugs: example of a collective approach. J Oncol Pharm Pract. 2011;17:252–9.CrossRefPubMed
3.
Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer. 2009;124:722–8.CrossRefPubMed
4.
Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci. 2008;30:161–8.CrossRefPubMed
5.
Easty AC, Coakley N, Cheng R, Cividino M, Savage P, Tozer R, et al. Safe handling of cytotoxics: guideline recommendations. Curr Oncol. 2015;22:e27–37.CrossRefPubMedPubMedCentral
6.
Gramage Caro T, Palomar Fernández C, Pueyo López C, Sánchez Cuervo M, Gómez de Salazar ME, Bermejo Vicedo T. Validating a classification scheme for medication errors to be used in chemotherapy. Farm Hosp. 2011;35:197–203.CrossRefPubMed
7.
Saad A, Der-Nigoghossian CA, Njeim R, Sakr R, Salameh P, Massoud M. Prescription errors with chemotherapy: quality improvement through standardized order templates. Asian Pac J Cancer Prev. 2016;17:2329–36.CrossRefPubMed
8.
Trudeau M, Green E, Cosby R, Charbonneau F, Easty T, Ko Y, et al. Key components of intravenous chemotherapy labeling: a systematic review and practice guideline. J Oncol Pharm Pract. 2011;17:409–24.CrossRefPubMed
9.
Ng T, Badry N, de Lemos ML. Rationalizing the use of auxiliary label for oral oncology drugs. J Oncol Pharm Pract. 2017;23:338–43.CrossRefPubMed
10.
11.
Dobish R, Shultz J, Neilson S, Raven A, Chambers CR. Worksheets with embedded checklists support IV chemotherapy safer practice. J Oncol Pharm Pract. 2016;22:142–50.CrossRefPubMed
12.
Gandhi S, Tyono I, Pasetka M, Trudeau M. Evaluating an oncology systemic therapy computerized physician order entry system using international guidelines. J Oncol Pract. 2014;10:e14–25.CrossRefPubMed
13.
Kukreti V, Cosby R, Cheung A, Lankshear S. ST computerized prescriber order entry guideline development group. Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful use. Curr Oncol. 2014;21:e604–12.CrossRefPubMedPubMedCentral
14.
Ortiz-Martin B, Pena-Cabia S. Degree of technological implementation in intravenous chemotherapy management in hospitals of the autonomous community of Madrid. Farm Hosp. 2017;41:488–96.PubMed
15.
Shulman LN, Miller RS, Ambinder EP, Yu PP, Cox JV. Principles of safe practice using an oncology EHR system for chemotherapy ordering, preparation, and administration, part 2 of 2. J Oncol Pract. 2008;4:254–7.CrossRefPubMedPubMedCentral
16.
Kullberg A, Larsen J, Sharp L. ‘Why is there another person’s name on my infusion bag?’ Patient safety in chemotherapy care—a review of the literature. Eur J Oncol Nurs. 2013;17:228–35.CrossRefPubMed
17.
Bubalo J, Warden BA, Wiegel JJ, Nishida T, Handel E, Svoboda LM, et al. Does applying technology throughout the medication use process improve patient safety with antineoplastics? J Oncol Pharm Pract. 2014;20:445–60.CrossRefPubMed
18.
Casiraghi A, Franzè S, Rocco P, Minghetti P. Risk management of in-hospital administration of anticancer drugs: impact of raccomandazione 14 from the Italian ministry of health. Tumori. 2016;102:2–6.CrossRefPubMed
19.
Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The clinical oncological society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol. 2010;6:220–37.CrossRefPubMed
20.
21.
22.
23.
24.
Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvet BE, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. Oncol Nurs Forum. 2017;44:31–43.CrossRefPubMed
25.
Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract. 2013;9:5s–13s.CrossRefPubMedPubMedCentral
26.
Jacobson JO, Polovich M, McNiff KK, LeFebvre KB, Cummings C, Galioto M, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum. 2009;36:651–8.CrossRefPubMed
27.
Goldspiel B, Hoffman JM, Griffith NL, Goodin S, DeChristoforo R, Montello CM, et al. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Health Syst Pharm. 2015;72:e6–35.CrossRefPubMed
28.
Greenall J, Shastay A, Vaida AJUD, Johnson PE, O’Leary J, et al. Establishing an international baseline for medication safety in oncology: findings from the 2012 ISMP international medication safety self assessment(R) for oncology. J Oncol Pharm Pract. 2015;21:26–35.CrossRefPubMed
29.
30.
Gilmore TR, Schulmeister L, Jacobson JO. Quality oncology practice initiative certification program: measuring implementation of chemotherapy administration safety standards in the outpatient oncology setting. J Oncol Pract. 2013;9:14s–8s.CrossRefPubMedPubMedCentral
31.
Griffin MC, Gilbert RE, Broadfield LH, Easty AE, Trbovich PL, Griffin MC, et al. ReCAP: comparison of independent error checks for oral versus intravenous chemotherapy. J Oncol Pract. 2016;12(168–9):e80–7.
32.
Ribed A, Escudero-Vilaplana V, Romero-Jiménez RM, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Séez M. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opin Drug Saf. 2016;15:427–35.CrossRefPubMed
33.
Lester J. Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. Clin J Oncol Nurs. 2012;16:E192–7.CrossRefPubMed
34.
Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7:7–12.CrossRefPubMedPubMedCentral
35.
Rudnitzki T, McMahon D. Oral agents for cancer: safety challenges and recommendations. Clin J Oncol Nurs. 2015;19:41–6.CrossRefPubMed
36.
37.
38.
Jara C, Ayala F, Virizuela JA. Oncology day hospital task force. The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward. Clin Transl Oncol. 2017;19:269–72.CrossRefPubMedPubMedCentral
39.
Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, et al. Revisions to the 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract. 2012;8:2–6.CrossRefPubMed
40.
Metadata
Title
Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients
Authors
R. Vera
M. J. Otero
F. Ayala de la Peña
C. González-Pérez
Á. Peñuelas
J. M. Sepúlveda
N. Quer
N. Doménech-Climent
J. A. Virizuela
P. Beorlegui
M. Q. Gorgas
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1945-x

Other articles of this Issue 4/2019

Clinical and Translational Oncology 4/2019 Go to the issue

Research Article

Effect of Paclitaxel-based Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on colonic anastomosis in a rat model

Research Article

Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis

Brief Research Article

Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

Research Article

Modulation of cancer cells’ radiation response in the presence of folate conjugated Au@Fe2O3 nanocomplex as a targeted radiosensitizer

Review Article

Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods?

Research Article

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits